epithalon oral vs subcutaneous injection differences bioavailability efficacy The of Drugs—The Current State of Knowledge epithalon oral vs subcutaneous differences

The short AOD-9604 half life presents both a challenge and an opportunity

Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Belec L et al (2007) Small molecule obatoclax (GX15070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis

study used oral administration in rodents, which is part of what attracted research interest

p53 N-terminal phosphorylation: a defining layer of complex regulation

The AEDG peptides documented interaction with histone proteins provides a specific molecular mechanism for this broader hypothesis

Claims that no side effects occur come mostly from the peptides inventors rather than independent investigators